To help obese and overweight Americans who have been unsuccessful in getting their weight under control with diet and exercise, the Food and Drug Administration (FDA) has approved four new weight loss medications since 2012 including Saxenda, Contrave, Belviq, and Qsymia. These weight loss drugs were approved, after a long gap of 13 years, for long-term weight management in addition to a reduced calorie diet and exercise program.
The first two weight loss drugs to be approved were Belviq and Qsymia in 2011.
Marketed as Belviq and Qsymia, these prescription medications would be taken for the rest of a person’s life. “For many people, obesity is a lifelong condition, but we don’t always think of it—or treat it—as such,” says Amy Egan, M.D., M.P.H., deputy director for safety in FDA’s Division of Metabolism and Endocrinology Products (DMEP).
Belviq is a prescription only weight loss medication and has to be evaluated by a trained and licensed physician familiar with obesity and the treatment of obesity. If you live close a W8MD medical weight loss center location, you may want to consider visiting the closest w8md center to be evaluated to see if Belviq, Qsymia, Contrave, Saxenda, Adipex P or other weight loss medications or non medication weight loss options such as VLCD or LCD diet might be right for you.
How Can W8MD Medical Weight Loss Centers Of America’s Program in NYC Help?
W8MD Medical Weight Loss Centers Of America announces that Belviq will be offered along with a low calorie diet at its medical weight loss lcoations under the supervision of a trained obesity medicine physician. With offices in many states including New York, Pennsylvania, and New Jersey, W8MD can help you lose weight safely and effectively using non-surgical weight loss measures such as FDA approved weight loss medications, Very Low Calorie and Low Calorie Diets, along with instructions on proper physical activity, you can lose weight safely and effectively.
Price of Belviq
Arena (ARNA) has disclosed that the wholesale price for its anti-obesity drug Belviq is $199.50 for a 60 count bottle (a 1 month supply). As per GoodRx, the retail price of Belviq might range from $210.00 to $260.00 per month.
Savings card or copay cards for Belviq for cost saving
From time to time, the manufacturer of Belviq, Qsymia, Contrave and other weight loss medications might offer certain discount cards or copay cards with certain limitations to help offset the cost of the weight loss medication. Certain government insurances such as Medicare, Medicaid etc. are usually excluded in these types of discount cards. Please check with the respective manufacturer or the local W8MD weight loss clinic to see if you might qualify to a discount card for any of these new weight loss medication.
As of May 2015, the manufacturer of Belviq, Arena Pharmaceuticals, offers a discount card that brings the patient cost to a maximum cost of $75.00 for commercial insurances and or self pay patients per month. Certain limitations, exclusions and other restrictions may apply. Please check the manufacturers website at http://www.Belviq.com.
When these discount cards or free trial offers are offered by the manufacturer of Belviq or other weight loss drug manufacturers, W8MD medical weight loss centers might be able to assist you in obtaining these coupons, discount cards and a valid prescription from a licensed weight loss physician after a consultation with the physician if medically appropriate.
The manufacturer of Belviq, Arena Pharmaceuticals, might also offer free trial of Belviq from time to time and is available via most W8MD weight loss center locations when these free trials are offered by the manufacturer for eligible weight loss patients. As of May 2015, a free two trial of Belviq is available.
“Qsymia and Belviq are considered life-long therapies in patients who respond to and tolerate them,” says Egan.
The drugs are meant to be used in conjunction with a balanced diet and exercise, says Mary Roberts, M.D., a medical officer in DMEP. “These drugs are another tool to be used by someone trying to reach and stay at a healthy weight,” she says.
• your body mass index (BMI) is 30 or greater (obese); or
• your BMI is 27 or greater (overweight) and you have at least one other weight-related condition.
Women who are pregnant or thinking of becoming pregnant should not take either of these medications, Ega n say s, because weight loss offers no potential benefit to a pregnant woman and can cause fetal harm.
Qsymia carries a risk for birth defects (cleft lip with or without cleft palate) in infants exposed during the first
trimester of pregnancy.
How Does Belviq Work?
Belviq —the trade name for the drug lorcaserin— is a 10 mg tablet taken twice a day that works by activating a part of the brain that controls hunger.
Belviq was tested in three clinical trials that lasted from 52 to 104 weeks and included nearly 8,000 obese and overweight patients.
• The average weight loss for patients taking Belviq ranged from 3 to 3.7 percent over those taking a placebo.
• In studies of patients without type 2 diabetes, about 47 percent of patients lost at least 5 percent of their weight
compared with 23 percent of patients treated with placebo.
Belviq should be discontinued if a patient fails to lose 5 percent of their weight after 12 weeks of treatment, as it is unlikely that continued treatment will be successful.
Alternatives to Belviq: Qsymia
Qsymia is a combination of two FDA-approved drugs: phentermine, an appetite suppressant, and topiramate, used to treat epilepsy and migraines. Roberts explains that Qsymia is taken once a day, with patients starting at the lowest dose(3.75 mg phentermine/23 mg topiramate extended-release), then increasing to the recommended dose (7.5 mg/46 mg). In some
circumstances, patients may have their dose increased to the highest dose (15 mg/92 mg).